FFRangio Accuracy vs. STandard FFR: Results from the FAST-FFR Trial

Slides:



Advertisements
Similar presentations
Disclosure Statement of Financial Interest
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation
To stent or not to stent Clinical Utility of Fractional Flow Reserve.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
DEFER STUDY: 5-YEAR FOLLOW-UP A Multicenter Randomized Study
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
PLATFORM: Economic and Quality of Life Outcomes of an FFR CT Diagnostic Strategy in Suspected CAD Mark A Hlatky, Bernard De Bruyne, Gianluca Pontone, Manesh.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Calculation From 3-Dimensional.
Afsane mohammadi,MD Interventional cardiologist.  The presence of inducible ischemia is an important risk factor for adverse outcome.the more inducible.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
J Am Coll Cardiol 2008;52:636–43 Comprehensive Assessment of Coronary Artery Stenoses Computed Tomography Coronary Angiography Versus Conventional Coronary.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Simplifying Serial Lesion Assessment
Total Occlusion Study of Canada (TOSCA-2) Trial
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Disclosures Runlin Gao has received a research grant
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Invasive Assessment of Coronary Artery Disease
Fractional Flow Reserve Evaluation in Patients Considered for Transfemoral Transcatheter Aortic Valve Implantation: A Case Series Cardiology 2012;123:234–239.
Nico H.J. Pijls, William F. Fearon, Peter Jüni, and Bernard De Bruyne
Physiologic Lesion Assessment: Advantages and Pitfalls
Updates From NOTION: The First All-Comer TAVR Trial
Quantitative Flow Ratio (QFR)
Clinical Presentation
Solved & Unsolved Issues
Emerging FFR Non-Wire-based Technology
ADenosine Vasodilator Independent Stenosis Evaluation II
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203
The Tryton Bifurcation Trial:
Main Arena II, Tuesday, Oct. 31, First Report Investigations 2
FAVOR II Europe-Japan FAVOR II E-J
OCT-Guided PCI What needs to be done to establish criteria?
MACE Trial Rationale, Study Design, and Current Status
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
Fractional Flow Reserve Workshop
Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,
A Randomized, Prospective, Intercontinental Evaluation of a Bioresorbable Polymer Sirolimus-eluting Stent: the CENTURY II Trial: an Update with 2 Years.
American College of Cardiology Presented by Dr. Stephan Windecker
European Society of Cardiology 2003
Giuseppe Biondi Zoccai, MD
Kyoto University Hospital, Japan
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Impact of Diabetes Mellitus on Long-term Outcomes in the
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

FFRangio Accuracy vs. STandard FFR: Results from the FAST-FFR Trial William F. Fearon, MD On Behalf of the FAST-FFR Study Investigators

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest /arrangement or affiliation with the organization(s) listed below Affiliation/Financial Relationship Company Institutional Grant/Research Support: Abbott, Medtronic, CathWorks, Consulting Fees/Honoraria: Boston Scientific Major Stock Shareholder/Equity Interest: Royalty Income: Ownership/Founder: Salary: Intellectual Property Rights: Other Financial Benefit: Stock Options HeartFlow

Background Measuring fractional flow reserve (FFR) with a coronary pressure wire to guide revascularization decisions in the catheterization laboratory has been shown to improve outcomes in a variety of clinical settings and is now included in multiple guideline statements.

Background FFR utilization, however, remains lower than expected because of a number of potential issues including the extra time it takes, wire handling characteristics, pressure wire drift, the need for hyperemia, and the expense. For all of these reasons, a technique for deriving FFR without the need of a pressure wire or hyperemic agent would be advantageous and could increase the adoption of physiology-guided revascularization.

Background Coronary angiography-derived FFR (FFRangio) is a new method for measuring FFR without a coronary pressure wire or hyperemic agent. FFRangio relies on creating a three-dimensional (3D) reconstruction of the coronary arterial system and estimating the resistance and flow at each point along the entire coronary tree.

Hemodynamic evaluation Background 1 Extracting centerlines Tree topology 3D model reconstruction 2 Bifurcation analysis 2D-QCA analysis Estimating diameters Stenosis assessment 3 Resistance mapping Maximum blood flow Flow rate ratio Hemodynamic evaluation 4 Optimal 2D angiography Optimal projections Optimal frame Motion compensation FFRangio is calculated as the ratio of the maximal flow rate in the stenosed artery compared with the flow rate in the absence of the stenosis

Background Preliminary studies have found that FFRangio when measured off-site by experienced operators correlates well with pressure wire-derived FFR. FFRangio has not been well validated when performed on-site by independent, local operators blinded to pressure wire-derived FFR and compared with core laboratory analyzed FFR values in a large, prospective, multicenter fashion.

Methods Objective The FAST-FFR study is a prospective, multicenter, international trial comparing the accuracy of on-site FFRangio with pressure wire-derived FFR.

Patients undergoing coronary angiography 3 roll-in patients / site 350 study patients 380 patients in total FFR of ≥ 1 lesion as part of standard care Reviewed by core-lab at CRF Simultaneous blinded FFRangio on-site Reviewed by core-lab at CathWorks

Methods Inclusion Criteria Adult patients with stable angina, unstable angina, or non-ST elevation acute coronary syndromes undergoing coronary angiography with coronary pressure wire-derived FFR measurement of a coronary stenosis

Methods Clinical Exclusion Criteria STEMI within the past 12 months Prior CABG, valve surgery, or heart transplantation Severe aortic stenosis LV Ejection Fraction ≤ 45%

Methods Angiographic Exclusion Criteria Left main stenosis > 50% Chronic total occlusion in target vessel < TIMI 3 flow in target vessel In-stent restenosis or recent stent placement in target vessel Severe diffuse disease Target vessel receiving collaterals

Methods Coronary Angiography Performed at each site per standard of care at a cine frame rate of at least 10 frames/second. Obtained at different projections (the exact inclination of the C-arm was left to the operator's ‎discretion)‎, with the entire vessel visualized, with adequate contrast opacification, avoiding vessel overlap, and without panning the table or moving the image intensifier.

Methods Pressure Wire-Derived FFR Any commercially available pressure wire system FFR measured in standard fashion with intravenous or intracoronary adenosine or intracoronary papaverine Pressure drift checked on pullback. If > ±0.03, the pressure wire was to be re-equalized and FFR was to be remeasured FFR tracings were sent to FFR core laboratory for review, blinded to FFRangio values

Methods FFRangio At least 3 DICOM videos of the vessel of interest were transferred immediately to the FFRangio console A hospital operator then calculated the FFRangio blinded to the pressure wire-derived FFR The FFRangio result was then sent to the core laboratory for review

Methods Co-Primary Endpoints Sensitivity & Specificity of FFRangio as compared with pressure wire-derived FFR using a cutoff value ≤ 0.80. Powered to meet the lower bound of the 95% CI for pre-defined performance goals set at: Sensitivity = 0.70 Specificity = 0.75

Methods Secondary Endpoints Diagnostic accuracy of FFRangio Correlation between FFRangio and FFR FFRangio device success

Results Enrollment by Site PI Site Country Enrollment Stephane Achenbach University of Erlangen Germany 67 Thomas Engstrom Rigshospitalet Denmark 64 Abid Assali Rabin Medical Center Israel 59 Allen Jeremias St. Francis Hospital United States 56 Stephane Fournier OLV Aalst Belgium 33 William Fearon Stanford University 32 Ajay Kirtane Columbia University 25 Gabriel Greenberg HaSharon Medical Center 19 Rami Jubeh Shaare Zedek Medical Center 16 Daniel Kolansky University of Pennsylvania 11

Results Subject Flowchart

Results Baseline Characteristic n=301 patients Age 64.7 ± (9.7) Male 74.1% Body Mass Index (kg/m2) 28.9 ± (4.8) Hypertension 69.1% Hypercholesterolemia 76.4% Diabetes Mellitus 31.9% Smoking (current or former) 52.8% Left Ventricular Ejection Fraction (LVEF) 58 ± (6)% Family history of coronary artery disease 39.3% Prior STEMI 3.3% Prior PCI with stent 29.2% Presentation Acute coronary syndrome (UA or NSTEMI) Stable patients 41.9%‎ 57.2%

Results Angiographic Result n=319 vessels Lesions per patient 1.1 ±0.3 Target Vessel LAD RCA LCX Ramus 54.2% 24.1% 19.1% 2.5% % Diameter Stenosis (Visual) 63 ±17% % Diameter Stenosis (QCA) 51 ±10% Lesion and Vessel Characteristics Bifurcation Moderate/Severe Tortuosity Moderate/Severe Calcification Lesion Class B or C 17.3% 5.5% 19.9% 88.8%

FFR and FFRangio Case Example

FFR and FFRangio Case Example

Results FFR and FFRangio Results Physiologic Result  FFR Mean 0.81 ± (0.13) Median 0.83 (0.74, 0.90) % of positive lesions (≤ 0.80) 43.3% % within 0.70-0.90 58.9% % within 0.75-0.85 31.3% FFRangio 0.80 ± (0.12) 0.82 (0.73, 0.89) 45.5% 63.6% 31.0% FFRangio was successfully measured in 98.7% of cases

Results Primary and Secondary Endpoints Diagnostic Characteristic   Sensitivity ‎93.5% ‎(87.8, 96.6) Specificity ‎91.2% ‎(86.0, 94.6)‎ Diagnostic accuracy 92.2% (88.7, 94.8) ‎Positive Predictive Value‎ 89.0% (82.6, 93.2) Negative Predictive Value‎ 94.8% (90.3, 97.3) Accuracy around FFR cutpoint (0.75-0.85) Sensitivity 88.5% Specificity 85.1%‎ Diagnostic accuracy 86.9% The diagnostic characteristics were similar when using the site reported FFR values, as opposed to the core laboratory’s values, as well as after including the roll-in cases.

Between FFRangio and FFR Results Correlation and Bland Altman Plot r=0.80, p<0.001 0.12 -0.14 Mean of FFRangio and FFR Pressure Wire-Derived FFR FFRangio Between FFRangio and FFR Absolute Difference The area under the curve on the ROC plot was 0.94

Results Characteristic Concordant (N = 277) Discordant (N = 24) P value Age 64.7 ± (9.7) 64.6 ± (9.8) 0.52 Male 74.1% 73.3% 0.28 Body Mass Index (kg/m2) 28.9 ± (4.8) 28.8 ± (4.9) 0.07 Hypertension 69.1% 69.0% 0.85 Hypercholesterolemia 76.4% 76.5% 0.87 Diabetes Mellitus 31.9% 32.1% 0.77 Smoking (current or former) 52.8% 53.4% 0.48 Left Ventricular Ejection Fraction (LVEF) 58 ± (6)% 0.99 Family history of coronary artery disease 39.3% 39.9% 0.53 Presentation Acute coronary syndrome (UA or NSTEMI) Stable patients 41.5%‎ 44.8% 45.8% 33.3% 0.68

Results Characteristic Concordant (N = 297) Discordant (N = 25) P value Target vessel LAD RCA LCX Ramus   55.9% 22.6% 19.5% 2.0% 32.0% 40.0% 20.0% 8.0% 0.03 0.04 0.14 0.09 % Diameter Stenosis (Visual estimation) 63 ± (17) 63 ± (9.8) 0.88 Mean FFR 0.80 ± (0.13) 0.83 ± (0.07) 0.16 FFR ≤ 0.80 43.9% 36.0% 0.42 Mean FFRangio 0.80 ± (0.12) 0.79 ± (0.08) 0.52 FFRangio ≤ 0.80 64.0% 0.05

Limitations We did not specifically assess the time it takes to calculate FFRangio in comparison to pressure wire-derived FFR. Some important patient subsets including left main disease, low ejection fraction and in-stent restenosis were not included and will require further study.

Summary FFR derived from routine coronary angiography (FFRangio) had very high sensitivity, specificity and diagnostic accuracy, all of which were greater than 90% for predicting the reference standard, coronary pressure wire-derived FFR. FFRangio and FFR remained highly correlated over the entire range of FFR values. FFRangio was successfully measured in almost all cases included.

Conclusion FFRangio may provide an easier and potentially faster method for performing physiology guided assessment of the overall coronary angiogram with similar accuracy to the reference standard, coronary pressure wire-based FFR. This may translate into a greater percentage of patients undergoing physiologic guidance for revascularization decisions and ultimately improve long-term outcomes.

Published on line Monday, September 24, 2018